Researchers have identified a key biological mechanism responsible for the poor prognosis seen in a subset of patients with diffuse large B-cell lymphoma (DLBCL), the most common aggressive form of lymphoma worldwide. In a new study published in Nature Genetics, an international team led by Goethe University Frankfurt, Universitätsmedizin Frankfurt, the German Cancer Consortium (DKTK), and the Frankfurt Cancer Institute discovered novel molecular features that can distinguish high-risk patients who are unlikely to respond to standard first-line treatment. The findings could pave the way for more personalized diagnostic and therapeutic strategies for this aggressive blood cancer.
Diffuse large B-cell lymphoma affects more than 150,000 people globally each year. Although the standard treatment regimen, typically consisting of a therapeutic antibody combined with chemotherapy (R-CHOP or Pola-R-CHP), cures nearly two-thirds of patients, more than one-third either relapse after treatment or fail to respond, requiring advanced therapies such as CAR T-cell therapy. Researchers have long sought reliable biomarkers that could identify these high-risk patients before treatment begins.
To better understand the disease, the research team analyzed tumor samples from 478 patients using an integrated multi-omics approach. The investigators examined genetic mutations, gene expression profiles, and protein production within tumor cells through proteomic analysis. Advanced artificial intelligence and interpretable machine learning models were then used to integrate these complex datasets, revealing previously unrecognized molecular patterns linked to treatment outcomes. The results were further validated using high-resolution single-cell tumor analyses.
The study identified a distinct high-risk subgroup of tumors, termed Proteogenotype 4 (PG4), characterized by activation of the MYC oncogene, a major driver of tumor growth and cell division. Despite arising from different genetic mutations, these tumors shared remarkably similar biological characteristics. Importantly, PG4 tumors were found to possess an immunologically "cold" microenvironment, with very few infiltrating immune cells and markedly suppressed cytotoxic T-cell activity, limiting the body's natural ability to recognize and destroy cancer cells.
Building on these findings, the researchers successfully inhibited MYC-associated molecular pathways in laboratory-grown PG4 lymphoma cells, selectively eliminating the cancer cells. This proof-of-concept demonstrates the potential for developing targeted therapies aimed specifically at this aggressive lymphoma subtype. According to the investigators, these newly identified molecular signatures could also serve as precision biomarkers for earlier identification of patients at greatest risk of treatment failure.
The researchers believe their findings represent a significant step toward personalized medicine in diffuse large B-cell lymphoma. By identifying high-risk patients earlier and matching them with therapies tailored to the unique biology of their tumors, future treatment strategies could improve survival rates and reduce the need for multiple rounds of unsuccessful therapy. While further clinical validation is required, the study offers promising new insights into overcoming one of the major challenges in the treatment of aggressive B-cell lymphoma.
